XGN VS UNH Stock Comparison

PerformanceSentimentTechnicalsEarningsProfitVolatilityAnalyst Price TargetsDividend
PerformanceSentimentTechnicalsEarningsProfitVolatilityAnalyst Price TargetsDividend

Performance

XGN
10/100

XGN returned -48.68% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

UNH
10/100

UNH returned 6.83% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Sentiment

XGN
68/100

XGN had a bullish sentiment score of 68.07% across Twitter and StockTwits over the last 12 months. It had an average of 2.75 posts, 0.12 comments, and 0.25 likes per day.

UNH

"Sentiment" not found for UNH

Technicals

XGN
14/100

XGN receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

UNH
89/100

UNH receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.

Earnings

XGN
33/100

XGN has missed earnings 4 times in the last 20 quarters.

UNH
100/100

UNH has missed earnings 0 times in the last 20 quarters.

Profit

XGN
10/100

Out of the last 20 quarters, XGN has had 0 profitable quarters and has increased their profits year over year on 0 of them.

UNH
81/100

Out of the last 20 quarters, UNH has had 20 profitable quarters and has increased their profits year over year on 11 of them.

Volatility

XGN
52/100

XGN has had a higher than average amount of volatility over the last 12 months giving it a score of 51 of 100.

UNH
49/100

UNH has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

Analyst Price Targets

XGN

"Analyst Price Targets" not found for XGN

UNH
88/100

22 analysts offer 12-month price targets for UNH. Together, they have an average target of 562.97, the most optimistic target put UNH at 650 within 12-months and the most pessimistic has UNH at 442.

Dividend

XGN

"Dividend" not found for XGN

UNH
57/100

UNH's most recent dividend was $0.90 per share, based on a share price of $540.46. It was a payout ratio of 28.49% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Exagen Inc. Common Stock Summary

Nasdaq / XGN
Healthcare
Medical - Diagnostics & Research
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

UNITEDHEALTH GROUP INCORPORATED (Delaware) Summary

New York Stock Exchange / UNH
Healthcare
Medical - Healthcare Plans
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance and health care programs; health and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.